Calidi Biotherapeutics financials
$1.08+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$20.2M | -$21.8M | -$29.0M |
| Net income | -$25.6M | -$23.8M | -$29.2M |
| Net margin | — | — | — |
| Diluted EPS | $-95.20 | $-571.20 | $-3327.36 |
| EBITDA | -$18.6M | -$20.2M | -$28.6M |
| Operating cash flow | -$21.3M | -$19.7M | -$27.0M |
| Free cash flow | -$21.4M | -$19.7M | -$27.6M |
| Diluted shares | 0.3M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $5.6M | $9.6M | $1.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $882.0K | $1.1M | $2.9M |
| Total assets | $8.9M | $14.2M | $10.0M |
| Total liabilities | $5.1M | $12.2M | $18.3M |
| Shareholders' equity | $3.8M | $2.0M | -$8.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology